Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812

Tuesday, October 24, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: A recent poster presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference highlights a Phase 2 clinical trial analyzing plasma proteomics in Alzheimer's patients. The study focuses on identifying pharmacodynamic biomarkers associated with the S2R modulator CT1812. This research aims to enhance the understanding of treatment effects in Alzheimer's disease.
Price reaction · baseline $1.24 (2023-10-23 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study aims to identify biomarkers for Alzheimer's treatment.
  • CT1812 is a promising S2R modulator being tested in patients.
  • The research contributes to understanding Alzheimer's disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Lizama B, Cho E, Duong D, et al. Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812 . Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD) ; Boston, Massachusetts.

Frequently Asked Questions

What is the focus of the CT1812 trial?

The trial focuses on identifying pharmacodynamic biomarkers in Alzheimer's patients.

Where was the CT1812 study presented?

The study was presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference.

What is CT1812?

CT1812 is an S2R modulator being tested for its effects on Alzheimer's disease.

What type of analysis was conducted in the trial?

A proteomic analysis of plasma samples from Alzheimer's patients was conducted.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare CT1812 Alzheimer's disease biomarkers clinical trial proteomic analysis
Last updated: Oct 24, 2023

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →